Dr. Jonathan T. Wolfe, MD
Dermatology (Procedural Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Georgetown University School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,107
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Georgetown University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Procedural Dermatology Physician primary
PA license MD054934L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jefferson Einstein Montgomery Hospital East Norriton, PA
Medical groups
- Dermatology Associates of Plymouth Meeting, P.c. (11 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,107
- Services billed
- 5,935
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 2,378 | 435 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,390 | 976 |
| Destruction of precancer skin growth, 1 growth | 718 | 539 |
| Biopsy of related skin growth, first growth | 449 | 379 |
| Biopsy of related skin growth, each additional growth | 171 | 106 |
| Destruction of precancer skin growth, 15 or more growths | 125 | 82 |
| Established patient office or other outpatient visit, 30-39 minutes | 116 | 102 |
| Established patient office or other outpatient visit, 10-19 minutes | 97 | 90 |
| Destruction of skin growth, 1-14 growths | 79 | 66 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 70 | 48 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 53 payments worth $1,222 in total to this clinician.
| Janssen Biotech, Inc. | $300 |
|---|---|
| AbbVie Inc. | $160 |
| UCB, Inc. | $129 |
| Regeneron Healthcare Solutions, Inc. | $118 |
| Genzyme Corporation | $98.45 |
| Leo Pharma Inc. | $80.61 |
| Pfizer Inc. | $60.81 |
| Galderma Laboratories, L.P. | $56.81 |
| Food and Beverage | $1,209 |
|---|---|
| Education | $13.17 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc Dec 10, 2025 | Education TREMFYA · Immunology · in-kind | $13.17 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 6 companies. The companies reported $938,690 in research payments for these studies, mostly to the institutions running them.
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Sun Pharmaceutical Industries Inc. - A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Incyte Corporation - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sanofi US Services Inc. · Completed · NCT06181435 - A phase 3 external and synthetic placebocontrolled randomized study with doseup for nonresponders to investigate safety and efficacy of ritlecitinib 50 mg and 100 mg once daily in adult and adolescent participants 12 …
Pfizer Inc. - A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
Pfizer Inc. - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Incyte Corporation - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Sanofi US Services Inc. · Active, not recruiting · NCT05492578 - M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.